[go: up one dir, main page]

MX2016014624A - Metodos para el tratamiento de enfermedad inflamatoria del intestino. - Google Patents

Metodos para el tratamiento de enfermedad inflamatoria del intestino.

Info

Publication number
MX2016014624A
MX2016014624A MX2016014624A MX2016014624A MX2016014624A MX 2016014624 A MX2016014624 A MX 2016014624A MX 2016014624 A MX2016014624 A MX 2016014624A MX 2016014624 A MX2016014624 A MX 2016014624A MX 2016014624 A MX2016014624 A MX 2016014624A
Authority
MX
Mexico
Prior art keywords
methods
ibd
smad7
subject
disclosed
Prior art date
Application number
MX2016014624A
Other languages
English (en)
Inventor
Giovanni Monteleone
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MX2016014624A publication Critical patent/MX2016014624A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describen métodos para tratar un sujeto con IBD con una terapia anti-SMAD7, como un oligonucleótido antisentido SMAD7, para reducir los niveles de CRP; también se describen procedimientos para tratar y controlar la IBD en un sujeto que usa una terapia anti-SMAD7, tal como un oligonucleótido antisentido SMAD7, basado en los niveles de PCR; también se describen métodos para determinar si un sujeto con IBD responde o es probable que responda al tratamiento de una terapia anti-SMAD7; la reducción de los niveles de CRP puede correlacionarse con la remisión de IBD o disminuciones en la puntuación CDAI; la presente invención también se refiere al tratamiento de IBD usando una terapia anti-SMAD7 (por ejemplo, un oligonucleótido antisentido) en combinación con un agente adicional; la invención también presenta composiciones y kits farmacéuticos relacionados.
MX2016014624A 2014-05-09 2015-05-08 Metodos para el tratamiento de enfermedad inflamatoria del intestino. MX2016014624A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461991326P 2014-05-09 2014-05-09
US201462065609P 2014-10-17 2014-10-17
US201462065606P 2014-10-17 2014-10-17
PCT/EP2015/060269 WO2015169966A2 (en) 2014-05-09 2015-05-08 Methods for treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
MX2016014624A true MX2016014624A (es) 2017-05-25

Family

ID=53059121

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014624A MX2016014624A (es) 2014-05-09 2015-05-08 Metodos para el tratamiento de enfermedad inflamatoria del intestino.

Country Status (11)

Country Link
US (1) US10473669B2 (es)
EP (1) EP3140658A2 (es)
JP (1) JP2017515896A (es)
KR (1) KR20170005058A (es)
CN (1) CN106573065A (es)
AU (1) AU2015257589A1 (es)
CA (1) CA2948411A1 (es)
MA (1) MA39963A (es)
MX (1) MX2016014624A (es)
RU (1) RU2016147569A (es)
WO (1) WO2015169966A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
SMT201700346T1 (it) 2008-11-13 2017-09-07 Nogra Pharma Ltd Composizioni antisenso e metodi per la loro preparazione e loro uso
CA2848595A1 (en) 2011-09-15 2013-03-21 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
ES2732252T3 (es) 2012-04-18 2019-11-21 Nogra Pharma Ltd Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
MX2016014624A (es) 2014-05-09 2017-05-25 Nogra Pharma Ltd Metodos para el tratamiento de enfermedad inflamatoria del intestino.
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
EP3420082A4 (en) * 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION
EP3420085A1 (en) * 2016-02-24 2019-01-02 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
CA3047302C (en) * 2016-12-14 2024-01-02 Tracy WARREN System and methods for developing and using a microbiome-based action component for patient health
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
US20200392491A1 (en) * 2017-07-28 2020-12-17 Nogra Pharma Limited Method of Preparing Oligonucleotide Compounds
WO2020112880A1 (en) * 2018-11-30 2020-06-04 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
TW202120521A (zh) 2019-08-16 2021-06-01 美商應用分子運輸公司 組合物、配方及介白素生產及純化
CA3173961A1 (en) * 2020-04-24 2021-10-28 Francesca Viti Compositions of smad7 antisense oligonucleotides (aso) and methods of using the same
EP4175676A4 (en) * 2020-07-06 2024-08-28 Vivtex Corporation MUCO-PENETRATING FORMULATIONS

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257932A1 (en) * 1997-02-28 2006-11-16 Yaron Ilan Treatment of Crohn's disease
ATE554169T1 (de) 2001-11-02 2012-05-15 Giuliani Int Ltd Smad7-inhibitoren zur behandlung von krankheiten des zns
EP1485127B1 (en) * 2002-02-25 2011-06-08 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20050118655A1 (en) * 2003-11-17 2005-06-02 University Of Iowa Research Foundation Use of parasitic biological agents for diseases prevention and control
SMT201700346T1 (it) 2008-11-13 2017-09-07 Nogra Pharma Ltd Composizioni antisenso e metodi per la loro preparazione e loro uso
CA2777800C (en) * 2009-10-15 2019-11-12 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
MX362132B (es) * 2011-05-10 2019-01-07 Nestec Sa Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.
CA2848595A1 (en) * 2011-09-15 2013-03-21 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
ES2732252T3 (es) 2012-04-18 2019-11-21 Nogra Pharma Ltd Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante
US20130316000A1 (en) * 2012-05-19 2013-11-28 Enoch Bortey Compositions and methods for treatment of irritable bowel syndrome with 5-aminosalicylate
US9772334B2 (en) * 2012-12-10 2017-09-26 The Regents Of The University Of California Inflammatory bowel disease markers and therapies for colitis-associated intestinal fibrosis
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
MX363746B (es) 2013-03-15 2019-04-01 Nogra Pharma Ltd Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal.
HK1223361A1 (zh) * 2013-05-24 2017-07-28 Société des Produits Nestlé S.A. 用於预测肠易激综合征诊断的途径特异性测定
MX2016014624A (es) 2014-05-09 2017-05-25 Nogra Pharma Ltd Metodos para el tratamiento de enfermedad inflamatoria del intestino.
US20170233736A1 (en) * 2014-10-17 2017-08-17 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3355896A2 (en) 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
EP3420085A1 (en) 2016-02-24 2019-01-02 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
US20190328770A1 (en) 2016-12-30 2019-10-31 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
KR20170005058A (ko) 2017-01-11
US10473669B2 (en) 2019-11-12
WO2015169966A3 (en) 2016-02-04
RU2016147569A (ru) 2018-06-13
CN106573065A (zh) 2017-04-19
RU2016147569A3 (es) 2018-12-28
CA2948411A1 (en) 2015-11-12
JP2017515896A (ja) 2017-06-15
US20180180630A1 (en) 2018-06-28
EP3140658A2 (en) 2017-03-15
WO2015169966A2 (en) 2015-11-12
AU2015257589A1 (en) 2016-11-24
MA39963A (fr) 2017-03-15

Similar Documents

Publication Publication Date Title
MA39963A (fr) Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
NZ707035A (en) Gene signatures of inflammatory disorders that relate to the liver
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EP3693736A3 (en) Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
MX2017003933A (es) Metodos de tratamiento de la enfermedad hepatica.
MA39906A (fr) Polythérapies pour le traitement du cancer
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
PH12019501010A1 (en) Arginase inhibitor combination therapies
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
PH12016502167A1 (en) Hdl theraphy markers
EP3634424A4 (en) Compositions and methods for preventing or treating muscle conditions
MY182454A (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX371017B (es) Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
EA201790802A1 (ru) Соединения против tnf
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
MX384423B (es) Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2).
MA40592A (fr) Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
NZ738100A (en) Igfbp3 and uses thereof
EA031679B9 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
EA201791933A1 (ru) Ингибирование активности olig2